Cargando…
Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous
KRAS mutant tumors are largely recalcitrant to targeted therapies. Genetically engineered mouse models (GEMMs) of Kras mutant cancer recapitulate critical aspects of this disease and are widely used for preclinical validation of targets and therapies. Through comprehensive profiling of exomes and ma...
Autores principales: | Chung, Wei-Jen, Daemen, Anneleen, Cheng, Jason H., Long, Jason E., Cooper, Jonathan E., Wang, Bu-er, Tran, Christopher, Singh, Mallika, Gnad, Florian, Modrusan, Zora, Foreman, Oded, Junttila, Melissa R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754767/ https://www.ncbi.nlm.nih.gov/pubmed/29203670 http://dx.doi.org/10.1073/pnas.1708391114 |
Ejemplares similares
-
Drugging an undruggable pocket on KRAS
por: Kessler, Dirk, et al.
Publicado: (2019) -
Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration
por: Lim, Yoong Wearn, et al.
Publicado: (2018) -
IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways
por: Song, Na-Young, et al.
Publicado: (2018) -
NETSeq reveals heterogeneous nucleotide incorporation by RNA polymerase I
por: Clarke, Andrew M., et al.
Publicado: (2018) -
Exploiting regulatory heterogeneity to systematically identify enhancers with high accuracy
por: Arbel, Hamutal, et al.
Publicado: (2019)